Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned for ...

Families say it's 'completely frustrating' that children with Duchenne Muscular Dystrophy are being denied access to free ...

Dyne Therapeutics (DYN) announced that the European Commission has granted orphan drug designation for DYNE-251 for the treatment of Duchenne ...

Key treatments for Alzheimer’s, rare cancers, and infectious diseases are under review, with new vaccines and therapies like ...

The orphan drug designation is particularly noteworthy as it can provide Dyne with a range of benefits, including reduced regulatory fees, assistance with clinical protocols, eligibility for research ...

The Jaffa Shriners’ DuBois Area Shrine Club continues to support a wheelchair program that provides essential equipment to ...

This year's Futures National Conference, hosted by CureDuchenne for the Duchenne and Becker MD communities, is scheduled to ...